Posted by Michael Wonder on 25 Aug 2016
NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
24 August 2016 - The National Institute of Health and Care Excellence (NICE) has published guidance not recommending ramucirumab in combination with docetaxel for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after platinum-based chemotherapy.
Guidance has been published in The Lancet Oncology.
